Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics
By Joanne T. Brindle, H. Antti, Edward C. Holmes, G. Tranter, Jeremy K. Nicholson, H. Bethell, S. Clarke, P. Schofield, E. McKilligin, D. Mosedale and 1 more. Nature Medicine, 2002
975 citations recorded by the source corpus.
Subfields: Complementary and alternative medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/c94a227b5ca607562be6bd66d7987dcef2fa3554
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- David S. Wishart
- Alisdair R. Fernie
- Jeremy K. Nicholson
- Joachim Kopka
- Edward C. Holmes
- James Kinross
- Nicolas Schauer
- John C. Lindon
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- The Human Urine Metabolome (2013, background): “This fact has made metabolomics particularly useful in the study of environment-gene interactions [1,2,3,4], the identification of disease biomarkers [5,6,7,8,9] and the discovery of drugs [10].”
- Gut microbiome-host interactions in health and disease (2011, methodology): “This analytical strategy has now been successfully applied to disease states such as hypertension [8], ischemic heart disease [56], diabetes [57] and obesity [58] as part of large-scale clinical studies.”
- Metabolomics for Investigating Physiological and Pathophysiological Processes. (2019, methodology): “Historically, metabolomics has been primarily used to diagnose diseases or detect pathological conditions (54, 175, 316, 350).”
- Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts (2007, background): “Metabonomics and metabolomics have also found application not only in the study of many disease”
- Metabolomics: a global biochemical approach to drug response and disease. (2008, background): “disease (25, 26), hypertension (27), subarachnoid hemorrhage (28), preeclampsia (29), type 2 diabetes (13, 30, 31), liver cancer (32), ovarian cancer (33), breast cancer (34), and Huntington’s disease (35).”
- Clinical biomarkers in drug discovery and development (2003, background): “and non-invasive imaging, through proton nuclear magnetic resonance (NMR), of the chemical composition of lipoproteins in patients with elevated serum lipid levels, potentially replacing angiograph”
- Comprehensive metabolic profiling and phenotyping of interspecific introgression lines for tomato improvement (2006, background): “Discussion Our study has shown that metabolite profiling has utility beyond diagnostic”